What Is Bone Cancer?

Bone cancer is a malignant tumor that arises in bone tissue itself, as opposed to secondary bone cancers that spread from other organs. Primary bone cancers are rare, accounting for less than 1% of all human malignancies, but they strike predominantly young people during their most active years. The three main types are osteosarcoma (most common, arising from osteoid-forming cells), Ewing sarcoma (arising from primitive mesenchymal cells), and chondrosarcoma (arising from cartilage-forming cells). Each has distinct biology, aggressiveness, and treatment response profiles.

In India, bone cancer presentation is typically late due to geographic healthcare gaps, limited specialist access in rural areas, and delayed referral chains. Many patients present with locally advanced or metastatic disease, which significantly impacts survival and functional outcomes. However, modern neoadjuvant chemotherapy (chemo given before surgery) combined with limb-salvage surgical techniques now allows the majority of adolescents and young adults to preserve their limbs and return to functional living.

The course of bone cancer spans diagnosis, staging, multimodal treatment (chemotherapy, surgery, sometimes radiation), rehabilitation, and long-term follow-up for recurrence. Early detection, aggressive chemotherapy according to established protocols, and surgical expertise in limb salvage are the cornerstones of improved outcomes. At HealOnco, we integrate these components into a coordinated care pathway that minimizes delays and maximizes both survival and quality of life.

Types of Bone Cancer

Signs and Symptoms

1. Bone pain: Persistent, often worsening pain at the site of the tumor, especially during night. Initially may be intermittent but becomes constant as the tumor grows. In adolescents, cannot be dismissed as ‘growth pain’ if localized, progressive, and unresponsive to rest.
2. Swelling and lump: A palpable mass or localized swelling over the affected bone. May be warm to touch. Swelling may restrict movement and cause visible asymmetry.
3. Limitation of movement: Reduced range of motion in joints adjacent to the tumor due to pain, swelling, or direct infiltration into soft tissue. Adolescents may report decreased athletic performance or inability to participate in sports.
4. Pathological fracture: Break in the bone at the site of the tumor, often from minor trauma or spontaneously. Presents acutely with severe pain and loss of function.
5. Limp or functional impairment: If tumor affects lower extremity or pelvis, may cause limping, avoidance of weight-bearing, or altered gait. Upper extremity tumors cause loss of fine motor control or shoulder/arm strength.
6. Constitutional symptoms (late sign): Fever, unintended weight loss, fatigue, and night sweats may indicate advanced or metastatic disease. Often accompanied by systemic symptoms of malignancy.
7. Respiratory symptoms (if lung metastases): Cough, chest pain, or shortness of breath if disease has spread to lungs. Lung involvement is the most common site of distant metastases in osteosarcoma and Ewing sarcoma.

Any bone pain persisting beyond 2-3 weeks, worsening at night despite rest, or accompanied by swelling in an adolescent or young adult warrants urgent evaluation. In India, delayed referral to tertiary centers often results in presentation with advanced local disease and occult metastases.

Risk Factors for Bone Cancer

While most bone cancers arise without identifiable risk factors, certain conditions and exposures increase risk. Below are evidence-based risk factors organized by strength of association:

Risk stratification based on published epidemiologic studies and AJCC guidelines. Most bone cancers occur without identifiable risk factors, emphasizing the importance of clinical awareness for early diagnosis.

How Bone Cancer Is Diagnosed

Diagnosis of bone cancer requires a multimodal approach integrating clinical history, imaging, and tissue confirmation. In India, delays in each step are common due to limited access to specialists and imaging modalities in rural areas. Prompt recognition of red-flag symptoms and rapid referral pathways are critical.

Staging and Prognosis (AJCC 8th Edition / Enneking Staging System)

Bone cancer staging determines treatment intensity, prognosis, and functional outcome predictions. The AJCC 8th Edition system and Enneking system are most commonly used. Metastatic status is the dominant prognostic factor.

Prognosis has improved dramatically with the introduction of multiagent chemotherapy in the 1970s-1980s. Current 5-year survival for localized osteosarcoma and Ewing sarcoma is 65-75%, compared to <20% in the pre-chemotherapy era. In India, late presentation with metastatic disease reduces these statistics; however, even metastatic patients benefit from intensive chemotherapy and surgical management. Prognostic factors include histologic response to neoadjuvant chemotherapy (>90% necrosis indicates good prognosis), alkaline phosphatase at diagnosis, and EWS-FLI1 type in Ewing sarcoma.

Treatment Options for Bone Cancer

Neoadjuvant Chemotherapy (Chemotherapy Before Surgery)

Neoadjuvant chemotherapy is given before surgery to shrink the primary tumor, improve surgical margins, treat micrometastatic disease, and assess chemotherapy responsiveness. The most established protocol for osteosarcoma is MAP (Methotrexate, Adriamycin [doxorubicin], Cisplatin), given in 4-5 cycles over 10-12 weeks. High-dose methotrexate (12 g/m2) requires hospitalization for infusion and folinic acid rescue; doxorubicin is infused on day 1-2; cisplatin (100-120 mg/m2) is given on day 4-6 with aggressive hydration and mesna uroprotection.

For Ewing sarcoma, the primary regimen combines VIDE (vincristine, ifosfamide, doxorubicin, etoposide) alternating with VAC (vincristine, adriamycin, cyclophosphamide) or IE (ifosfamide, etoposide). Five-year event-free survival is 65-75% with this approach in localized disease, improving to 75-80% when combined with radiation and surgery.

Chemotherapy toxicity includes nausea, vomiting, mucositis, myelosuppression, infection risk, cardiac toxicity (doxorubicin), neurotoxicity (vincristine), and renal toxicity (cisplatin, ifosfamide). Management includes antiemetics, growth factor support, antimicrobial prophylaxis, and fertility counseling (chemotherapy may cause infertility in both sexes). At HealOnco, oncologists monitor chemotherapy tolerance closely and adjust doses as needed.

Histologic response to neoadjuvant chemotherapy (measured as percent tumor necrosis at surgical specimen examination) is a powerful predictor of prognosis. Good response (>90% necrosis) predicts better 5-year survival (75-80%); poor response (<90% necrosis) may warrant escalation to second-line chemotherapy post-operatively.

• Methotrexate (high-dose, 12 g/m2 IV)
• Doxorubicin (Adriamycin, 25-30 mg/m2 IV)
• Cisplatin (100-120 mg/m2 IV with hydration)
• Vincristine (1.4 mg/m2 IV, max 2 mg)
• Ifosfamide (10-14 g/m2 IV with mesna)
• Etoposide (100 mg/m2 IV)
• Cyclophosphamide (500-1200 mg/m2 IV)
• Folinic acid (leucovorin, rescue agent for methotrexate)
• Mesna (uroprotective agent for ifosfamide)

Limb-Salvage Surgery

Limb-salvage surgery is surgical resection of the primary tumor with reconstruction to preserve limb function and appearance. Historically, amputation was the standard; now, 70-80% of patients with extremity osteosarcoma and Ewing sarcoma are candidates for limb salvage. Tumor resection requires a wide margin (2-5 cm of normal tissue around the tumor) to minimize local recurrence risk. After chemotherapy has response-assessed the tumor, wide local excision is performed with careful soft-tissue reconstruction.

Reconstruction methods depend on tumor location and extent: endoprosthetic replacement (metal implant mimicking the resected bone segment), allograft (cadaveric bone), autograft (bone from patient’s pelvis or other site), or rotationplasty (rotation of distal limb segment to function as a prosthetic joint). The choice balances oncologic control, functional outcome, limb length preservation, and complications.

Surgical teams include orthopedic surgical oncologists, vascular surgeons, and plastic surgeons. In India, tertiary centers in major cities offer these capabilities; access outside these centers requires patient travel and financial resources. At HealOnco, partnerships with high-volume orthopedic oncology centers ensure expertise in limb-salvage techniques.

Complications include infection, implant loosening or breakage (requiring revision), soft-tissue complications (wound dehiscence, hematoma), vascular compromise, and nerve injury. Long-term function depends on soft-tissue healing, limb length equality, and patient rehabilitation. Most patients achieve functional ambulation and return to some recreational activities, though high-impact sports may be restricted.

• Surgical modalities (not drugs): wide local excision, endoprosthetic replacement, allograft reconstruction, autograft reconstruction, rotationplasty
• Perioperative antibiotics (typically broad-spectrum IV during hospitalization, then oral fluoroquinolones or cephalosporins for wound healing phase)
• Analgesics: opioids (morphine, fentanyl) for post-operative pain; transition to acetaminophen and NSAIDs (avoiding NSAIDs in immediate post-op phase)

Amputation

Amputation—complete removal of the limb proximal to the tumor—is reserved for patients with tumor involvement of major blood vessels or nerves that cannot be reconstructed, very poor chemotherapy response, or recurrent/metastatic disease in a previously irradiated limb. Modern series show amputation in 20-30% of extremity cases and higher rates for pelvic tumors. Amputation rates are higher in India due to late presentation and resource constraints limiting reconstruction options.

Types include above-knee amputation (AKA), below-knee amputation (BKA), above-elbow amputation (AEA), or below-elbow amputation (BEA). Pelvic resection may require hemipelvectomy (removal of entire half of pelvis), resulting in significant functional and cosmetic impact. Post-amputation phantom limb pain occurs in 70-80% of amputees; management includes opioids, anticonvulsants (gabapentin, pregabalin), SSRIs, and psychological support.

Prosthetic fitting begins 4-6 weeks post-operatively, after wound healing and shrinkage of residual limb. Modern prosthetics offer excellent function for lower limb amputees (near-normal gait and return to sports possible with proper training). Upper limb prosthetics are less functional but improve quality of life. At HealOnco, post-amputation rehabilitation and prosthetic services are coordinated.

• Perioperative antibiotics (broad-spectrum IV)
• Analgesics: opioids (morphine, hydromorphone, fentanyl) for acute post-operative pain
• Phantom limb pain management: gabapentin (300-3600 mg/day divided), pregabalin (150-600 mg/day), sertraline (50-200 mg/day), duloxetine (60 mg/day)
• NSAIDs (ibuprofen, naproxen) for residual limb pain and inflammation

Radiation Therapy

External beam radiation therapy (EBRT) is used in selected cases: inadequate surgical margins, inoperable tumors, palliation of metastatic disease, or recurrent disease in the surgical bed. Typical doses are 50-70 Gy in 1.8-2.0 Gy daily fractions. For Ewing sarcoma, radiation is standard in cases with inadequate surgery or high risk of local failure. Proton therapy offers advantages (reduced exit dose) but availability in India is extremely limited.

Acute toxicity includes skin erythema, fatigue, nausea, and diarrhea (if abdomen in field). Late toxicity includes soft-tissue fibrosis, bone atrophy, joint stiffness, and secondary malignancy in the radiation field (increases risk 100-fold for sarcomas, 10-20% cumulative incidence by 20 years post-therapy). In children, growth disturbances and cosmetic deformities result from radiation to epiphyseal plates.

Intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) reduce dose to normal tissues compared to conventional 3D conformal therapy. In India, IMRT availability is limited to select urban centers; access barriers delay treatment for rural patients.

• Radiation delivery (not drugs): external beam radiation therapy (EBRT), IMRT, VMAT, proton therapy
• Supportive medications during radiation: antiemetics (ondansetron, granisetron), antimicrobial mouthwashes (chlorhexidine) if head/neck irradiation

Targeted and Molecular Therapies

For EWS-FLI1-positive Ewing sarcoma, the fusion oncoprotein is an attractive therapeutic target. Trabectedin (ET-743) is a DNA-binding drug that inhibits EWS-FLI1 transcriptional activity; phase 2 data show response rates of 25-30% in chemotherapy-refractory disease. Trofosfamide (ifosfamide analog) and reactivating p53 pathways (e.g., MDM2 inhibitors) are under investigation.

For chondrosarcoma and other advanced sarcomas, tyrosine kinase inhibitors (sorafenib, sunitinib) targeting FGFR and PDGFR pathways show modest activity in phase 2 trials. mTOR inhibitors (everolimus, temsirolimus) have been explored in bone sarcomas with mixed results.

For giant cell tumor, denosumab (anti-RANKL monoclonal antibody, Prolia) is approved and highly effective: recurrence reduced from 63% (post-curettage) to 35% in a pivotal trial. Denosumab is given as 120 mg subcutaneous monthly for 6 months pre-operatively, then post-operatively to reduce local recurrence. Toxicity includes hypocalcemia (requiring calcium/vitamin D supplementation), osteonecrosis of jaw (rare, <1%), and potential fetal toxicity (absolute contraindication in pregnancy).

Checkpoint inhibitors (anti-PD-1/PD-L1) are being studied in bone sarcomas; early data suggest modest benefit in combination with standard chemotherapy. Adoptive T-cell therapy and CAR-T cell approaches are investigational. In India, access to these agents is limited to select private institutions and clinical trials; cost is prohibitive for most patients.

• Denosumab (120 mg SC monthly, anti-RANKL monoclonal antibody for giant cell tumor)
• Calcium supplement (1000-1200 mg daily) and vitamin D (1000-2000 IU daily) with denosumab
• Trabectedin (ET-743, 1.3 mg/m2 IV over 24 hours for EWS-FLI1+ Ewing sarcoma)
• Sorafenib (400 mg PO BID for advanced sarcomas, experimental)
• Sunitinib (37.5 mg PO daily for advanced sarcomas, experimental)
• Everolimus (5-10 mg PO daily for mTOR inhibition, experimental)
• Nivolumab or pembrolizumab (anti-PD-1 checkpoint inhibitors, experimental)

Supportive Care and Symptom Management

Supportive care spans the entire treatment course and beyond. Pain management transitions from opioids (acute, perioperative) to non-opioid modalities (NSAIDs, acetaminophen, topical agents) and adjuvant drugs (gabapentin, pregabalin, duloxetine, tricyclic antidepressants) for chronic pain. Bone pain, phantom limb pain, and neuropathic pain from chemotherapy require individualized approaches.

Nutritional support is critical during chemotherapy. Mucositis, nausea, and altered taste necessitate dietary modifications (soft foods, small frequent meals, nutritional supplements). In India, malnutrition at diagnosis predicts worse outcomes; dedicated nutritionist involvement improves chemotherapy tolerance and outcomes.

Psychosocial support addresses cancer diagnosis impact, amputation/disfigurement adjustment, body image concerns, educational/vocational rehabilitation, and family coping. In India, cancer stigma and financial hardship are significant burdens; counseling and support groups are invaluable. At HealOnco, social workers and psychologists work alongside medical teams.

Rehabilitation begins immediately post-operatively for limb salvage and limb loss patients. Physiotherapy focuses on range of motion, strength, ambulation, and return to function. Occupational therapy addresses activities of daily living and adaptive strategies. Prosthetic training (for amputees) optimizes limb use and confidence. Return to school and work is encouraged with appropriate accommodations.

• Analgesics: acetaminophen (500-1000 mg QID), ibuprofen (200-800 mg TID-QID), naproxen (250-500 mg BID)
• Opioids (acute/perioperative): morphine (IV/PO dose-escalated), fentanyl (transdermal 12-100 mcg/72h, breakthrough IV/lollipop)
• Anticonvulsants for neuropathic pain: gabapentin (300-3600 mg/day divided), pregabalin (150-600 mg/day)
• Antidepressants: duloxetine (60 mg/day), amitriptyline (10-50 mg HS)
• Antiemetics: ondansetron (4-8 mg IV/PO TID), granisetron (1 mg IV/PO), dexamethasone (8-20 mg/day during chemotherapy)
• GI prophylaxis: proton pump inhibitor (pantoprazole 40 mg daily)
• Antimicrobial prophylaxis: fluoroquinolone (ciprofloxacin 500 mg BID) or cephalosporin during neutropenia
• Growth factor support: G-CSF (filgrastim, 5 mcg/kg SC daily) during chemotherapy-induced neutropenia
• Nutritional supplements: albumin, immunonutrition products (whey protein, branched-chain amino acids)
• Psychotropic medications: sertraline (50-200 mg/day), lorazepam (0.5-2 mg PRN for anxiety)

Why Adjuvant (Post-Operative) Chemotherapy Is Essential

Adjuvant chemotherapy after surgery is fundamental to bone cancer cure because microscopic metastatic disease is present in the majority of newly diagnosed osteosarcoma and Ewing sarcoma patients, despite negative imaging for distant metastases. Historical data show that surgery alone (without chemotherapy) results in 80-90% relapse rates. The introduction of multiagent chemotherapy in the 1970s-1980s reduced relapse to 20-35%, transforming a universally fatal diagnosis into a curable disease.

Chemotherapy eradicates micrometastatic cells in lung, bone marrow, and other sites, preventing distant relapse. The chemotherapy regimen is identical whether metastases are clinically evident at diagnosis or not: MAP (methotrexate, doxorubicin, cisplatin) for osteosarcoma and VIDE/VAC for Ewing sarcoma. Typically 6-10 cycles total are given (4-5 neoadjuvant + 2-5 adjuvant). Adjuvant cycles continue even if metastases are found during treatment, ensuring maximal chemotherapy exposure.

Histologic response to neoadjuvant chemotherapy (percent tumor necrosis at surgical pathology) is the single most important prognostic factor. Patients with >90% necrosis have 75-80% 5-year survival; those with poor response (<90% necrosis) face 40-50% 5-year survival. Some centers escalate post-operative chemotherapy (second-line agents like ifosfamide, etoposide) for poor responders, though survival benefit remains uncertain.

In India, adjuvant chemotherapy completion is challenged by treatment cost, distance to tertiary centers, toxicity burden, family caregiver availability, and competing household priorities. Early treatment abandonment predicts relapse and death. At HealOnco, supportive services (travel assistance, hospitalization, toxicity management) aim to ensure completion of the prescribed chemotherapy course, recognizing that adherence directly correlates with long-term survival.

A Day at HealOnco: The Bone Cancer Treatment Journey

Cost Overview: Bone Cancer Treatment in India

Bone cancer treatment costs vary significantly based on treatment modality (chemotherapy, surgery, radiation), facility type (government tertiary center vs. private hospital), and complications. Below are representative costs in Indian Rupees (INR) for common scenarios. Government hospitals may subsidize 50-100% for eligible patients; private facilities charge full cost. Many families face catastrophic financial burden and may skip adjuvant chemotherapy or pursue alternate medicine.

Costs exclude lost wages, travel/lodging for patient and caregiver, opportunity costs, and indirect expenses. Financial toxicity is a major cause of treatment non-completion in India; many families delay diagnosis recognition, attempt unproven remedies, or abandon adjuvant chemotherapy due to cost. Government schemes (Ayushman Bharat, state cancer programs) provide partial coverage but often require lengthy paperwork and may not cover all modalities. NGOs and HealOnco’s patient support services aim to bridge this gap and ensure equitable access to evidence-based care.

Our Bone Cancer Specialists

Our Centres

Modern vs. Traditional Approach to Bone Cancer

Pros and Cons of Treatment Modalities

Neoadjuvant Chemotherapy (Pros): Proven to improve 5-year survival from <20% (surgery alone) to 65-75%; allows tumor downsizing enabling limb salvage in majority of patients; provides early assessment of chemotherapy responsiveness (histologic response predictive of prognosis); treats occult micrometastatic disease; allows time for prosthetic or reconstruction planning.

Neoadjuvant Chemotherapy (Cons): Significant toxicity (nausea, myelosuppression, infection risk, neuropathy, cardiotoxicity, nephrotoxicity); requires 10-12 weeks of hospitalization/clinic visits (burden for rural India families); delays surgery by 2-3 months (risk of tumor progression, though rare with appropriate monitoring); may require central venous catheter placement (infection risk); cost burden (INR 300,000–500,000 in private sector).

Limb-Salvage Surgery (Pros): Preserves limb and functional anatomy; better psychosocial outcomes (body image, self-esteem) compared to amputation; 90%+ patients achieve functional ambulation and return to work/school; improved quality of life long-term; allows return to sports (with limitations); cosmetically superior to amputation.

Limb-Salvage Surgery (Cons): Technically demanding, requiring expertise available only in select centers; higher operative time (4-6 hours) increasing infection and anesthetic risk; implant cost substantial (INR 600,000–1,500,000 in private sector); implant complications (loosening, breakage, infection) requiring revision surgery; soft-tissue flaps may have healing complications; growth of pediatric patients may cause implant length mismatch requiring future revision; long-term implant durability uncertain in young patients.

Amputation (Pros): Simpler, faster operative procedure (2-3 hours) with lower infection risk; lower cost (INR 250,000–600,000); definitive oncologic control (no risk of residual disease); eliminates chronic pain/functional limitation of limb salvage failure; historically only option; excellent prosthetic outcomes for well-motivated amputees.

Amputation (Cons): Severe psychological trauma (loss of identity, self-image, independence); phantom limb pain in 70-80% of patients (often severe and refractory); high rates of depression and social isolation post-amputation; prosthetic fitting challenging in India due to cost and access; gait asymmetry and energy expenditure higher than intact limb; sports/recreation limitations; prosthetic maintenance and replacement costs ongoing.

Radiation Therapy (Pros): Effective for inadequate surgical margins or inoperable disease; non-invasive, no surgical risk; can be targeted to recurrent lesions; useful for palliation of painful metastases; available in most tertiary centers.

Radiation Therapy (Cons): Late toxicity (secondary malignancy risk 100-fold increase, cumulative incidence 10-20% by 20 years); soft-tissue fibrosis and joint stiffness; growth impairment and cosmetic deformities in children; limited availability of IMRT/proton therapy in India (causing treatment delays and increased normal tissue dose); protracted treatment course (6-7 weeks); potential impact on future fertility/bone health.

Denosumab for Giant Cell Tumor (Pros): Dramatic reduction in recurrence from 63% to 35%; can enable limb salvage in previously amputation-destined cases; non-surgical option for unresectable GCT; improves pain and function; monthly subcutaneous injection simple logistics.

Denosumab for Giant Cell Tumor (Cons): Hypocalcemia risk (requires calcium/vitamin D supplementation); osteonecrosis of jaw (rare, <1%); long-term safety data limited (drug approval relatively recent); pregnancy absolute contraindication; cost prohibitive in India (monthly cost INR 50,000–100,000); requires long-term follow-up for recurrence despite treatment.

Side Effects and HealOnco’s Management

Read the full side effects guide for Bone Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Bone Cancer Treatment in Top Cities

Bone Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. Gorlick R, et al. Osteosarcoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 11th ed. Wolters Kluwer; 2019. pubmed.ncbi.nlm.nih.gov
2. DeLaney TF, Hornicek FJ. Ewing’s Sarcoma. In: DeVita VT, et al. eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 11th ed. Wolters Kluwer; 2019. pubmed.ncbi.nlm.nih.gov
3. National Comprehensive Cancer Network (NCCN). Bone Cancer. Clinical Practice Guidelines. Version 1.2024. www.nccn.org
4. American Academy of Orthopaedic Surgeons (AAOS). Osteosarcoma: Diagnosis and Treatment. OrthoInfo. 2023. orthoinfo.aaos.org
5. Meyers PA, et al. Chemotherapy for non-metastatic osteosarcoma: toward better outcomes—report of the musculoskeletal tumor society. Cancer. 2011;117(12):2735-2743. pubmed.ncbi.nlm.nih.gov
6. Whelan JS, et al. Biology and therapy of Ewing sarcoma family tumors. Eur J Cancer. 2011;47 Suppl 3:S294-S305. pubmed.ncbi.nlm.nih.gov
7. Thomas DM, Broadhead ML, Lobo S. Molecular aspects of giant cell tumor of bone. Ortho Surg. 2011; 3(3):165-172. pubmed.ncbi.nlm.nih.gov
8. Rutkowski P, et al. Denosumab in giant cell tumor of bone: a review of efficacy and safety. Curr Opin Oncol. 2023;35(4):282-289. pubmed.ncbi.nlm.nih.gov
9. Raikar VA, et al. Cancer epidemiology in India: Present and future. Indian J Surg Oncol. 2012;3(4):379-384. pubmed.ncbi.nlm.nih.gov
10. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. In: Jaffe N, Bruland OS, Bielack S, eds. Pediatric Bone and Soft Tissue Sarcomas: Biology, Therapy and Translation. Springer; 2016. pubmed.ncbi.nlm.nih.gov
11. Casali PG, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guideline. Ann Oncol. 2018;29 Suppl 4:iv79-iv95. pubmed.ncbi.nlm.nih.gov
12. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6(7):1075-1085. pubmed.ncbi.nlm.nih.gov